Skip Navigation

Cardiovascular Research 1998 38(1):198-205; doi:10.1016/S0008-6363(97)00324-6
© 1998 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tahara, A.
Right arrow Articles by Tanaka, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tahara, A.
Right arrow Articles by Tanaka, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1998, European Society of Cardiology

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte

Atsuo Tahara*, Yuichi Tomura, Koh-ichi Wada, Toshiyuki Kusayama, Junko Tsukada, Noe Ishii, Takeyuki Yatsu, Wataru Uchida and Akihiro Tanaka

Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka, Tsukuba, Ibaraki 305, Japan

* Corresponding author. Tel.: +81 (298) 54-1568; fax: +81 (298) 52-2955; e-mail: tahara@yamanouchi.co.jp

Objective: Hypertrophy of cardiomyocytes may play an important role in the pathogenesis of cardiac hypertrophy associated with various cardiovascular diseases such as congestive heart failure. The aim of this study was to investigate whether vasopressin (AVP) induces protein synthesis in cultured neonatal rat cardiomyocytes through its specific receptor and whether YM087, a newly synthesized nonpeptide AVP receptor antagonist, inhibits AVP-induced protein synthesis in vitro. Methods: AVP receptors on cardiomyocytes were characterized using the radioligand [3H]AVP. The effects of AVP and YM087 on intracellular free calcium concentration ([Ca2+]i), mitogen-activated protein (MAP) kinase and [3H]-leucine incorporation were investigated in cultured neonatal rat cardiomyocytes. Results: In cardiomyocytes, Scatchard analysis showed a single population of high-affinity binding sites with the expected AVP V1A receptor subtype profile. YM087 showed high affinity for cardiomyocyte V1A receptors with a Ki value of 0.63 nM. In these same cells, YM087 potently inhibited AVP-induced increases in [Ca2+]i and activation of MAP kinase in a concentration-dependent manner. In addition, AVP concentration-dependently stimulated the synthesis of protein without changing the rate of DNA synthesis, and YM087 prevented AVP-induced protein synthesis in a concentration-dependent manner. Conclusions: These results suggest that AVP directly causes protein synthesis and YM087 is a potent inhibitor of AVP-induced protein synthesis of cardiomyocytes and thus may have beneficial effects in the development and regression of cardiomyocytic hypertrophy.

KEYWORDS Vasopressin; Vasopressin receptors; Vasopressin receptor antagonists; YM087; V1A receptor; Rat; Cardiomyocytes


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
J. E. Udelson, F. A. McGrew, E. Flores, H. Ibrahim, S. Katz, G. Koshkarian, T. O'Brien, M. W. Kronenberg, C. Zimmer, C. Orlandi, et al.
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study on the Effect of Oral Tolvaptan on Left Ventricular Dilation and Function in Patients With Heart Failure and Systolic Dysfunction
J. Am. Coll. Cardiol., June 5, 2007; 49(22): 2151 - 2159.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
E. Cristia, C. Amat, R. J. Naftalin, and M. Moreto
Role of vasopressin in rat distal colon function
J. Physiol., January 15, 2007; 578(2): 413 - 424.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley
Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2397 - 2409.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
L. C. Costello-Boerrigter, W. B. Smith, G. Boerrigter, J. Ouyang, C. A. Zimmer, C. Orlandi, and J. C. Burnett Jr.
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
Am J Physiol Renal Physiol, February 1, 2006; 290(2): F273 - F278.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. R. Goldsmith and M. Gheorghiade
Vasopressin Antagonism in Heart Failure
J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1785 - 1791.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
C. Woischwill, P. Karczewski, H. Bartsch, H.-P. Luther, M. Kott, H. Haase, and I. Morano
Regulation of the human atrial myosin light chain 1 promoter by Ca2+-calmodulin-dependent signaling pathways
FASEB J, April 1, 2005; 19(6): 503 - 511.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Sanghi, B. F. Uretsky, and E. R. Schwarz
Vasopressin antagonism: a future treatment option in heart failure
Eur. Heart J., March 2, 2005; 26(6): 538 - 543.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
L. Li, J. J. Galligan, G. D. Fink, and A. F. Chen
Vasopressin Induces Vascular Superoxide Via Endothelin-1 in Mineralocorticoid Hypertension
Hypertension, March 1, 2003; 41(3): 663 - 668.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. Naitoh, J. Risvanis, L. C. Balding, C. I. Johnston, and L. M. Burrell
Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition
Cardiovasc Res, April 1, 2002; 54(1): 51 - 57.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. E. Udelson, W. B. Smith, G. H. Hendrix, C. A. Painchaud, M. Ghazzi, I. Thomas, J. K. Ghali, P. Selaru, F. Chanoine, M. L. Pressler, et al.
Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure
Circulation, November 13, 2001; 104(20): 2417 - 2423.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.